IBM
IBM Watson Health Strategic Failure
Estimated impact: $5B
IBM invested over $5 billion acquiring companies and building Watson Health, promising AI-driven healthcare transformation. The technology consistently failed to deliver on marketing claims, with oncology recommendations sometimes being unsafe. IBM sold the division for approximately $1 billion in 2022.
Decision context
Whether to continue investing billions in Watson Health's AI-driven oncology and healthcare analytics products despite repeated failures to match clinical accuracy claims in real-world settings.
Biases present in the decision
Toxic combinations
- Optimism Trap
- Sunk Ship
Reference class base rates
Across all 146 curated case studies in our library:
Lessons learned
- Marketing AI capabilities before the technology can reliably deliver creates a credibility gap that erodes customer trust.
- Planning fallacy in AI healthcare deployments consistently underestimates the difficulty of working with messy, unstructured clinical data.
- Confirmation bias led IBM to showcase cherry-picked success stories while ignoring systemic accuracy failures.
Source: Casey Ross and Ike Swetlitz, "IBM's Watson Supercomputer Recommended Unsafe and Incorrect Cancer Treatments" (STAT News, 2018) (News Investigation)
See what we'd flag in your next strategic memo.
Upload a strategic memo or board deck. Get the same bias audit you just saw for IBM, on your own high-stakes call, in under 60 seconds.
Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.
Ready to audit your own memo right now? Create a free account →